Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Sigilon Therapeutics to Present at Upcoming Scientific and Investor Conferences

Sigilon Therapeutics
Posted on: 24 Feb 18

CAMBRIDGE, Mass., Feb. 23, 2018 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conferences. Presentation details are as follows:

National Hemophilia Foundation 14th Workshop on Novel Technologies and Gene Transfer for Hemophilia



Implantation of Immune Protected Cell Factories Protected by AfibromerTM Technology for the Treatment of Hemophilias 


 David Peritt, Ph.D., Chief Technology Officer  


Saturday, Feb. 24, 2018  


10:45 a.m. EST 


Capitol Hyatt Regency, Washington, D.C. 

BioCentury 25th Annual Future Leaders in the Biotech Industry Conference



Paul Wotton, Ph.D., Chief Executive Officer  


Friday, March 23, 2018 


1:30 p.m. EDT  


Millennium Broadway Hotel & Conference Center, New York  

About Sigilon Therapeutics

Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics' Afibromer™ technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

For more information please visit or follow on Twitter at

Editor's Details

Mike Wood

Last updated on: 24/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.